A Controversial Alzheimer’s Drug Has Gone Down in Flames
Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...
Cassava Sciences Faces Reality After Simufilam's Phase 3 Failure
Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...
pharmaphorum4d
End looms for Cassava's simufilam in Alzheimer's disease
Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...
Monthly Prescribing Reference5d
No Significant Improvement With Simufilam in Alzheimer Disease Trial
Simufilam is an investigational oral small molecule that targets the filamin A protein. In the ReThink-ALZ study (ClinicalTrials.gov Identifier: NCT04994483 ), patients with confirmed mild or moderate ...
Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results
Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...
Cassava taps Freda Nassif as chief commercial officer as simufilam Phase 3 readout nears
Her appointment comes at a critical time as the company prepares for its first Phase 3 data readout before year-end 2024 for ...
Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
Simufilam did not show a significant reduction in cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s ...
Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study
Cassava Sciences shares are plunging in premarket trading and are losing most of their value after the biotech firm said its ...